WELL Health Technologies Corp. reports developments across a Canadian outpatient healthcare platform, digital health software and related technology-enabled services. The company operates a large owned clinic network in Canada and reports recurring updates on patient visits, Canadian Patient Services, primary care and specialty care performance, acquisitions, clinic transformation activity and financial results.
WELL’s news also covers WELLSTAR healthcare technology products, including electronic medical records, AI-powered clinical tools, patient engagement, eReferral and IT managed services. Other recurring themes include HEALWELL AI, CYBERWELL cybersecurity services, virtual cardiology through CardiologyNow, partnerships for remote cardiac monitoring, conference participation and financing capacity for the company’s healthcare operations.
WELL Health Technologies (WHTCF) reported record Q3-2026 revenue of $407.4 million, with Canadian Patient Services driving growth in the quarter. Revenue rose 12% year over year, while adjusted EBITDA, a non-standard earnings measure, fell 15% to $50.9 million. Excluding Circle Medical deferred revenue recognized in the prior-year quarter, revenue and adjusted EBITDA increased 17% and 20%, respectively.
Canadian Patient Services revenue rose 49% to $164.9 million; adjusted EBITDA rose 82% to $25.7 million, reaching a $100 million annualized run-rate one quarter early. Net loss widened to $135.5 million from $2.7 million, including impairment and WELLSTAR listing costs. WELL reaffirmed 2026 adjusted EBITDA guidance of $185 million–$195 million and updated revenue guidance to approximately $1.58 billion. WELLSTAR completed its public listing, and WELL issued $150 million of notes, using part of the proceeds to redeem convertible debt.
WELL Health Technologies (WHTCF) will release its third-quarter 2026 financial results after market close on November 9, 2026. The results cover the period ended September 30, 2026.
A conference call and simultaneous webcast will follow that day at 5:30 pm EST, hosted by Chairman and Chief Executive Officer Hamed Shahbazi and Chief Financial Officer Evelyn Sutherland.
WELL Health Technologies (WHTCF) and HEALWELL AI announced that the Competition Bureau concluded its review of WELL's controlling-interest acquisition of HEALWELL.
The No Action Letter, issued October 22, 2026, confirms that the Commissioner of Competition does not, at this time, intend to apply under section 92 of the Competition Act regarding the transaction. WELL completed its acquisition on April 1, 2025; the transaction also included HEALWELL's concurrent acquisition of Orion Health.
In December 2025, the Bureau announced that it had obtained a Federal Court order requiring records and information relating to the transaction. WELL and HEALWELL cooperated throughout the review and supplied the requested material.
WELL Health Technologies (WHTCF) appointed Samara Starkman Chief Privacy Officer and Vice President, Legal & Regulatory, effective immediately.
Starkman joins WELL's Law Department to lead enterprise privacy, AI governance and healthcare regulatory initiatives across WELL Health, WELLSTAR and HEALWELL AI. Her mandate includes building a scalable privacy program and developing an AI governance framework. She previously led the privacy department at Cancer Care Ontario, now part of Ontario Health, co-founded INQ Consulting and served as a partner at INQ Law.
WELL Health Technologies (WHTCF) will present at the Cantech Investment Conference in Toronto on October 8, 2026. Chief Executive Officer Hamed Shahbazi will deliver the investor presentation at 9:00 AM ET in Track 1. Chief Operating Officer Derek Clark will participate in scheduled one-on-one investor meetings. The conference will take place at the Arcadian Loft.
WELL Health Technologies (WHTCF) has launched WELL Research/b, a consolidated, end-to-end clinical trial platform and brand built on its Canadian outpatient and technology network as of September 22, 2026.WELL Research combines three core offerings: (i) full-service Contract Research Organization (CRO) trial management for early-phase studies, (ii) Site Management Organization (SMO) services handling recruitment and coordination at late-stage trial sites, and (iii) bioanalytical services across trial phases, therapeutic areas, and therapy modalities.
The platform is supported by four assets: Canada’s largest outpatient clinic network with 275 clinics and over 5 million annual patient visits, the WELLSTAR network of 45,000+ providers, the WELLTrust consent platform with 100,000+ consented patients, and HEALWELL AI’s DARWEN system for AI-based feasibility and participant matching. WELL Research comprises BioPharma Services and Canadian Phase Onward, held through a clinical research joint venture with HEALWELL AI.
WELL Health Technologies (WHTCF) has appointed Evelyn Sutherland as Chief Financial Officer, effective September 21, 2026, as part of a planned transition.
Sutherland, who has over 20 years of senior financial leadership experience and has completed more than 50 acquisitions and divestitures, previously held CFO roles at Staples Canada, Enercare, KEYreit and United Purchasing Group of Canada. She has served on the board of WELL subsidiary WELLSTAR for the past year, gaining direct insight into WELL’s strategy and governance.
Long-serving CFO Eva Fong will step down from the CFO role and become a strategic Executive Advisor, supporting an orderly handover. WELL describes itself as Canada’s largest outpatient healthcare company, operating 275 clinics and supporting more than 5 million annual patient visits through its clinic network and technology platforms.
WELL Health Technologies (WHTCF) reports that its WELLTRUST™ database has surpassed 100,000 patient consents since launching in February 2026. Each consented WELL patient has agreed to be contacted about clinical trials and research studies that match their health circumstances. The milestone was reached organically through in-clinic enrollment using WELLSTAR's OceanMD platform, which embeds a revocable consent step into digital check-in and writes the record to the patient chart.
HEALWELL's DARWEN™ AI matches trial protocols to this standing, consented population to deliver pre-screened participants to sponsors. WELL and HEALWELL outline a three-phase roadmap targeting about one million consented patients, deeper EMR connectivity across roughly 275 clinics, new digital consent channels, and future U.S. and European expansion.
WELL Health Technologies (TSX: WELL, OTCQX: WHTCF) redeemed early all of its outstanding 5.50% convertible senior unsecured debentures due December 31, 2026. On August 19, 2026, the company paid holders in cash and the debentures ceased trading and were delisted from the TSX.
The redeemed debentures, previously trading under symbol WELL.DB, had an aggregate principal of $70 million. Holders received $1,007.3333 per $1,000 principal, including $7.3333 of accrued interest. According to WELL Health, the redemption was funded with cash on hand, supported by its inaugural $150 million senior unsecured notes offering completed in July.
WELL Health (OTCQX: WHTCF) reported record Q2-2026 revenue of $400.4 million, up 12% year-over-year, led by Canadian Patient Services revenue of $151.6 million, up 32%. Adjusted EBITDA was $48.1 million (down 3%), with a 12% margin, impacted by prior-year Circle Medical deferrals.
Adjusted Gross Profit rose 12% to $178.4 million (44.6% margin). The company recorded a net loss of $7.8 million versus prior net income of $17.0 million, while Adjusted Net Income fell to $11.6 million ($0.04 per share). WELL closed the OID Group and UnionMD acquisitions, lifting its Canadian clinic network to 275 clinics and WELL Canada’s annualized Adjusted EBITDA run-rate to over $100 million, ahead of plan.
Subsequently, WELL completed a $150 million 6.875% senior unsecured notes offering due 2031 and supported WELLSTAR’s planned TSXV listing via an RTO and $50 million subscription receipts financing. The company raised 2026 revenue guidance to $1.58–$1.65 billion and Adjusted EBITDA guidance to $185–$195 million.